• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Closing the evidence gap in the use of emerging testing technologies in clinical practice.弥合临床实践中新兴检测技术应用方面的证据差距。
JAMA. 2008 Dec 3;300(21):2542-4. doi: 10.1001/jama.2008.754.
2
The incorporation of new technologies into genetic services; the importance of government support.将新技术融入基因服务；政府支持的重要性。
Birth Defects Orig Artic Ser. 1992;28(3):126-30.
3
Scenario drafting to anticipate future developments in technology assessment.情景起草以预测技术评估的未来发展。
BMC Res Notes. 2012 Aug 16;5:442. doi: 10.1186/1756-0500-5-442.
4
When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.何时以及如何评估快速变化的技术：四种通用技术在医学应用方面的比较研究
Health Technol Assess. 1997;1(14):i-vi, 1-149.
5
Road Map For Diffusion Of Innovation In Health Care.医疗创新扩散路线图
Health Aff (Millwood). 2018 Feb;37(2):198-204. doi: 10.1377/hlthaff.2017.1155.
6
The new NICE Evaluation Pathway for medical technologies.英国国家卫生与临床优化研究所（NICE）新的医疗技术评估途径。
Ann R Coll Surg Engl. 2010 Jul;92(5):435-6.
7
The innovation of success: the pediatric surgery and APSA response to "disruptive technologies".成功的创新：小儿外科与美国小儿外科医师协会对“颠覆性技术”的回应。
J Pediatr Surg. 2009 Jan;44(1):1-12. doi: 10.1016/j.jpedsurg.2008.10.004.
8
Reducing wasteful innovation.减少浪费性创新。
Qual Prim Care. 2013;21(5):267-8.
9
Actor-network theory: a tool to support ethical analysis of commercial genetic testing.行动者网络理论：一种支持商业基因检测伦理分析的工具。
New Genet Soc. 2003 Dec;22(3):271-96. doi: 10.1080/1463677032000147225.
10
Coverage with evidence development: an examination of conceptual and policy issues.基于证据生成的覆盖范围：概念与政策问题审视
Int J Technol Assess Health Care. 2007 Fall;23(4):425-32. doi: 10.1017/S0266462307070651.

引用本文的文献

1
The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies.癌症靶向治疗的药物基因组学检测实施流程。
J Pers Med. 2018 Oct 1;8(4):32. doi: 10.3390/jpm8040032.
2
Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.癌症的药物基因组学和多基因检测的保险覆盖政策。
J Pers Med. 2018 May 16;8(2):19. doi: 10.3390/jpm8020019.
3
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.使基因组医学具有循证性和以患者为中心：比较有效性研究的结构化综述和全景分析。
Genet Med. 2017 Oct;19(10):1081-1091. doi: 10.1038/gim.2017.21. Epub 2017 Apr 13.
4
Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013.实践中的药物基因组学与治疗诊断学：2013年5月欧洲医学实验室 - 欧洲药物基因组学与治疗诊断学学会（Euromedlab - ESPT）卫星研讨会综述
EJIFCC. 2013 Feb 21;24(3):85-9. eCollection 2013 Feb.
5
Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.一项指导早期非小细胞肺癌辅助化疗决策的预后测试的成本效益分析
Oncologist. 2016 Feb;21(2):196-204. doi: 10.1634/theoncologist.2015-0162. Epub 2015 Nov 27.
6
Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.搭上精准医疗的列车：非遗传学家临床医生入门指南：第3部分。精准医疗领域的临床应用
Curr Psychiatry Rev. 2014 May;10(2):118-132. doi: 10.2174/1573400510666140630170549.
7
Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample.美国一个基于概率的在线样本中遗传性结直肠癌基因检测的价值。
Med Decis Making. 2015 Aug 1;35(6):734-744. doi: 10.1177/0272989X14565820. Epub 2015 Jan 14.
8
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.美国国立癌症研究所指定癌症中心对乳腺癌、肺癌和胃食管癌进行生物标志物检测。
J Natl Cancer Inst. 2014 Sep 12;106(10). doi: 10.1093/jnci/dju256. Print 2014 Oct.
9
The economic value of personalized medicine tests: what we know and what we need to know.个性化医疗检测的经济价值：我们已知的和需要了解的。
Genet Med. 2014 Mar;16(3):251-7. doi: 10.1038/gim.2013.122. Epub 2013 Oct 17.
10
Utilization of HER2 genetic testing in a multi-institutional observational study.在一项多机构观察性研究中 HER2 基因检测的应用。
Am J Manag Care. 2012 Nov;18(11):704-12.

本文引用的文献

1
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?基因组医学中的翻译研究连续统一体：我们如何加速将人类基因组发现合理整合到医疗保健和疾病预防中？
Genet Med. 2007 Oct;9(10):665-74. doi: 10.1097/GIM.0b013e31815699d0.
2
Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.保险公司与癌症“靶向生物制剂”：与李·N·纽科默的对话。芭芭拉·J·卡利顿采访
Health Aff (Millwood). 2008 Jan-Feb;27(1):w41-51. doi: 10.1377/hlthaff.27.1.w41. Epub 2007 Nov 27.
3
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.曲妥珠单抗在辅助治疗HER2阳性乳腺癌中的成本效益分析。
Cancer. 2007 Aug 1;110(3):489-98. doi: 10.1002/cncr.22806.
4
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.早期HER2/neu阳性乳腺癌辅助曲妥珠单抗治疗方案的成本效益分析
J Clin Oncol. 2007 Feb 20;25(6):634-41. doi: 10.1200/JCO.2006.06.3081.
5
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.曲妥珠单抗辅助治疗人表皮生长因子受体2阳性乳腺癌的成本效益
J Clin Oncol. 2007 Feb 20;25(6):625-33. doi: 10.1200/JCO.2006.06.4220.
6
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
7
Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.健康保险状况对乳腺癌患者诊断检查中HER-2/neu检测纳入情况的影响。
Int J Qual Health Care. 2004 Dec;16(6):517-21. doi: 10.1093/intqhc/mzh085.
8
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.HER-2检测与曲妥珠单抗治疗转移性乳腺癌的成本效益分析
J Clin Oncol. 2004 Mar 1;22(5):854-63. doi: 10.1200/JCO.2004.04.158.

Closing the evidence gap in the use of emerging testing technologies in clinical practice.

作者信息

Phillips Kathryn A

机构信息

Center for Translational and Policy Research on Personalized Medicine, School of Pharmacy, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94143-0613, USA.

出版信息

JAMA. 2008 Dec 3;300(21):2542-4. doi: 10.1001/jama.2008.754.

DOI:10.1001/jama.2008.754
PMID:19050197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2910511/
Abstract
摘要